Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 107-116

  Westland, Chris ^a   Delaney IV, William ^a   Yang, Huiling ^a   Chen, Shan Shan ^a   Marcellin, Patrick ^b   Hadziyannis, Stephanos ^c   Gish, Robert ^d   Fry, John ^a   Brosgart, Carol ^a   Gibbs, Craig ^a   Miller, Michael ^a   Xiong, Shelly ^a  

^a GILEAD SCIENCES   (United States)

^b BEAUJON HOSPITAL   (France)

^c HENRY DUNANT HOSPITAL   (Greece)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; ASIA; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; GENE AMPLIFICATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; NORTH AMERICA; OCEANIC REGIONS; PHASE 3 CLINICAL TRIAL; PHYLOGENY; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SOUTHERN EUROPE; WESTERN EUROPE;

EID: 0037772440     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00700-5     Document Type: Article

References (42)

1. Robertson BH, Margolis HS. Primate hepatitis B viruses - genetic diversity, geography and evolution. Rev Med Virol 2002;12:133-141.
2. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
3. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69:2575-2583.
4. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
5. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
6. Burda MR, Gunther S, Dandri M, Will H, Petersen J. Structural and functional heterogeneity of naturally occurring hepatitis B virus variants. Antiviral Res 2001;52:125-138.
7. Baumert TF, Blum HE. Hepatitis B virus mutants: molecular biology and clinical relevance. Viral Hepatitis Rev 2000;6:177-192.
8. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
9. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999;6:299-304.
10. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-1209.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
12. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35:1274-1276.
13. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
14. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, Haussinger D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-725.
15. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
16. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, Lai ME, Belussi F, Busatto G, Balestrieri A, Ruol A, Alberti A. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-589.
17. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate ML, Manzini P, Capalbo M, Piantino P, Verme G, Bonino F. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-850.
18. Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, Pastore G, Ideo G, Bonino F, Brunetto MR. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999;94:1366-1372.
19. Zollner B, Petersen J, Schafer P, Schroter M, Laufs R, Sterneck M, Feucht HH. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-1277.
20. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-935.
21. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, the Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
23. Yang H, Westland CE, Delaney IV WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
24. Felsenstein J. PHYLIP (Phylogeny Inference Package). Version 3.5c. Seattle; Department of Genetics, University of Washington; 1993. Available at: http://evolution.genetics.washington.edu/ phylip/faq.html#citation.
25. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996;12:357-358.
26. Swenson PD, Van Geyt C, Alexander ER, Hagan H, Freitag-Koontz JM, Wilson S, Norder H, Magnius LO, Stuyver L. Hepatitis B virus genotypes and HBsAg subtypes in refugees and injection drug users in the United States determined by LiPA and monoclonal EIA. J Med Virol 2001;64:305-311.
27. Moriya T, Kuramoto IK, Yoshizawa H, Holland PV. Distribution of hepatitis B virus genotypes among American blood donors determined with a PreS2 epitope enzyme-linked immunosorbent assay kit. J Clin Microbiol 2002;40:877-880.
28. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 1997;175:1285-1293.
29. Vieth S, Manegold C, Drosten C, Nippraschk T, Gunther S. Sequence and phylogenetic analysis of hepatitis B virus genotype G isolated in Germany. Virus Genes 2002;24:153-156.
30. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-267.
31. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Kumada H. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002;37:35-39.
32. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993;67:5402-5410.
33. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994;91:4077-4081.
34. Bhat RA, Ulrich PP, Vyas GN. Molecular characterization of a new variant of hepatitis B virus in a persistently infected homosexual man. Hepatology 1990;11:271-276.
35. Kato H, Orito E, Gish RG, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol 2002;76:6131-6137.
36. Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002;35:922-929.
37. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
38. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999;29:976-984.
39. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000;31:763-768.
40. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-971.
41. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
42. Heathcote EJ, Thai Q, Margulies M, Tsiang M, Fry J, Gibbs CS, Westland C, Xiong S, Yang H, Namini H, Brosgart C. Adefovir dipivoxil (ADV) for HBeAg negative chronic hepatitis B (HBV): virological & comparative viral dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral clearance. J Hepatol 2001;34(Suppl 1):167.